CN100471955C - A fusion gene, its expressed protein and its preparation method - Google Patents
A fusion gene, its expressed protein and its preparation method Download PDFInfo
- Publication number
- CN100471955C CN100471955C CNB200410056850XA CN200410056850A CN100471955C CN 100471955 C CN100471955 C CN 100471955C CN B200410056850X A CNB200410056850X A CN B200410056850XA CN 200410056850 A CN200410056850 A CN 200410056850A CN 100471955 C CN100471955 C CN 100471955C
- Authority
- CN
- China
- Prior art keywords
- ctb
- chain
- human insulin
- fusion gene
- silkworm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 49
- 230000004927 fusion Effects 0.000 title claims abstract description 31
- 102000004169 proteins and genes Human genes 0.000 title claims description 15
- 238000002360 preparation method Methods 0.000 title description 4
- 101500025354 Homo sapiens Insulin B chain Proteins 0.000 claims abstract description 34
- 241000255789 Bombyx mori Species 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 9
- 241000701447 unidentified baculovirus Species 0.000 claims description 11
- 241000700605 Viruses Species 0.000 claims description 7
- 230000003321 amplification Effects 0.000 claims description 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 230000001926 lymphatic effect Effects 0.000 claims 1
- 235000016623 Fragaria vesca Nutrition 0.000 abstract description 12
- 235000011363 Fragaria x ananassa Nutrition 0.000 abstract description 12
- 108020001507 fusion proteins Proteins 0.000 abstract description 11
- 102000037865 fusion proteins Human genes 0.000 abstract description 11
- 241000699670 Mus sp. Species 0.000 abstract description 7
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract description 7
- 235000013399 edible fruits Nutrition 0.000 abstract description 7
- 241001465754 Metazoa Species 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 3
- 208000015181 infectious disease Diseases 0.000 abstract description 2
- 238000002347 injection Methods 0.000 abstract description 2
- 239000007924 injection Substances 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 241000486679 Antitype Species 0.000 abstract 1
- 240000009088 Fragaria x ananassa Species 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 235000013305 food Nutrition 0.000 abstract 1
- 238000010353 genetic engineering Methods 0.000 abstract 1
- 230000002705 inhibitory effect on diabetes Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 102000009016 Cholera Toxin Human genes 0.000 description 35
- 108010049048 Cholera Toxin Proteins 0.000 description 35
- 238000012546 transfer Methods 0.000 description 15
- 239000013612 plasmid Substances 0.000 description 14
- 241000220223 Fragaria Species 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 210000000087 hemolymph Anatomy 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 241001203868 Autographa californica Species 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
- 230000000981 bystander Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000005965 immune activity Effects 0.000 description 2
- 230000006058 immune tolerance Effects 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000021012 strawberries Nutrition 0.000 description 2
- 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 2
- 241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000255794 Bombyx mandarina Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102100032378 Carboxypeptidase E Human genes 0.000 description 1
- 108010058255 Carboxypeptidase H Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 1
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710182846 Polyhedrin Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000006870 ms-medium Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
Abstract
本发明属于生物技术制药工程中的基因工程生产多肽类药物技术领域。构建了CTB与人胰岛素B链融合基因,并在家蚕幼虫、蛹和草莓果实中高效表达了CTB与人胰岛素B链融合蛋白,经动物口服试验,对小鼠具有明显的抑制糖尿病的作用,成为一种制备抗I型糖尿病药物的新型方法。与现有技术相比,原料易得,生产成本低,具有口服或鲜食的优点,为患者解除了注射的痛苦和被感染的威胁,治疗效果良好,具有十分重大的市场开发应用前景。
The invention belongs to the technical field of polypeptide drug production by genetic engineering in biotechnology pharmaceutical engineering. The fusion gene of CTB and human insulin B chain was constructed, and the fusion protein of CTB and human insulin B chain was highly expressed in silkworm larvae, pupae and strawberry fruit. After animal oral test, it had obvious inhibitory effect on diabetes in mice, becoming A novel method for preparing anti-type I diabetes medicine. Compared with the prior art, the raw material is easy to obtain, the production cost is low, and it has the advantages of oral or fresh food, relieves the pain of injection and the threat of infection for patients, has good therapeutic effect, and has very significant market development and application prospects.
Description
技术领域 technical field
本发明涉及一种融合基因、其表达的蛋白以及制备方法。具体来说,本发明涉及CTB与人胰岛素B链融合基因、其表达的蛋白以及其制备方法。The invention relates to a fusion gene, its expressed protein and a preparation method. Specifically, the present invention relates to CTB and human insulin B chain fusion gene, its expressed protein and its preparation method.
背景技术 Background technique
I型糖尿病(胰岛素依赖性糖尿病,IDDM)由胰岛素分泌缺陷产生,它是一种针对胰岛β细胞的自身免疫性疫病。虽然导致IDDM的自身抗原包括胰岛素谷氨酸脱羧酶、胰岛素、热休克蛋白、羧基肽酶H等多种抗原,但是实验中仅给动物口服一种自身抗原-胰岛素,即诱导了免疫耐受,产生了保护作用(Science,1994,265:1237)。这是由于口服抗原能诱导调节性T细胞分泌抑制性细胞因子,如TGF-β,对由相互间无关的各种抗原诱导的、但在同一特异器官发生的所有病理免疫反应进行抑制,即抗原驱动旁观者抑制(Antigen-drivenBystander Suppression)。旁观者抑制的诱导是抗原特异性的,而效应是非特异的,这为预防I型糖尿病等自身免疫疾病提供了一条新的途径(Immunol Today,1998,19:173)。同时,研究表明霍乱毒素B亚基(CTB)可作为诱导口服耐受的强大粘膜运载系统,并且CTB偶联抗原可能涉及到与传统大剂量口服自身抗原产生免疫耐受效应明显不同的免疫调节机制,可能涉及到发炎细胞的移动行为的变化(NatBiotechnol,1998,16,292),暗示CTB偶联自身抗原不仅使应用口服耐受防治I型糖尿病等自身免疫性疫病更具有实际应用价值,而且还有潜在的治疗前景(Proc Natl Acad Sci USA,1997,94:4610)。Type I diabetes (insulin-dependent diabetes mellitus, IDDM) results from defective insulin secretion and is an autoimmune disease targeting pancreatic beta cells. Although autoantigens that cause IDDM include insulin glutamic acid decarboxylase, insulin, heat shock protein, carboxypeptidase H and other antigens, only one autoantigen-insulin was orally administered to animals in the experiment, which induced immune tolerance. A protective effect was produced (Science, 1994, 265:1237). This is because oral administration of antigens can induce regulatory T cells to secrete inhibitory cytokines, such as TGF-β, which can inhibit all pathological immune responses induced by various antigens that are not related to each other but that occur in the same specific organ, that is, antigen Drive bystander suppression (Antigen-drivenBystander Suppression). The induction of bystander suppression is antigen-specific, while the effect is non-specific, which provides a new way to prevent autoimmune diseases such as
发明内容 Contents of the invention
本发明的目的之一是提供一种CTB与人胰岛素B链融合基因。One of the objectives of the present invention is to provide a fusion gene of CTB and human insulin B chain.
本发明的目的之二是提供CTB与人胰岛素B链融合基因表达的蛋白。The second object of the present invention is to provide the protein expressed by fusion gene of CTB and human insulin B chain.
本发明的目的之三是提供一种制备表达CTB与人胰岛素B链融合基因的蛋白的方法。The third object of the present invention is to provide a method for preparing a protein expressing fusion gene of CTB and human insulin B chain.
本发明通过如下技术方案来实现。The present invention is realized through the following technical solutions.
(1)构建含有CTB与人胰岛素B链融合基因的转移质粒pBac-CTBINB和pBI-CTBINB。设计2条引物P1和P2,以pBac-CTBINS质粒(见200310121132.1专利申请说明书)为模板、P1和P2为引物进行扩增,获得融合基因CTB-INB。融合基因序列及其编码的氨基酸序列分别如SEQ ID NO.1和SEQ ID NO.2所示。将目的片段经BamHI和EcoRI双酶切后,连接在同样被BamHI和EcoRI双酶切的转移载体pBacPAK8上,构建含CTB与人胰岛素B链融合基因的杆状病毒转移质粒pBac-CTBINB。进一步将pBac-CTBINB经BamHI和SacI双酶切后,连接在同样被BamHI和SacI双酶切的转移载体pBI121上,构建含CTB与人胰岛素B链融合基因的植物转移质粒pBI-CTBINB。(1) Construction of transfer plasmids pBac-CTBINB and pBI-CTBINB containing the fusion gene of CTB and human insulin B chain. Design two primers P1 and P2, use pBac-CTBINS plasmid (see 200310121132.1 patent application description) as a template, and P1 and P2 as primers to amplify to obtain fusion gene CTB-INB. The fusion gene sequence and its encoded amino acid sequence are respectively shown in SEQ ID NO.1 and SEQ ID NO.2. The target fragment was double-digested with BamHI and EcoRI, and connected to the transfer vector pBacPAK8, which was also double-digested with BamHI and EcoRI, to construct the bacmid transfer plasmid pBac-CTBINB containing the fusion gene of CTB and human insulin B chain. Further, pBac-CTBINB was digested with BamHI and SacI, and then connected to the transfer vector pBI121, which was also digested with BamHI and SacI, to construct the plant transfer plasmid pBI-CTBINB containing the fusion gene of CTB and human insulin B chain.
P1<SEQ ID NO.3>:5′CGGGATCCATGATTAAATTAAAATTTGG3′P1 <SEQ ID NO.3>: 5′CGGGATCCATGATTAAATTAAAATTTGG3′
P2<SEQ ID NO.4>:5′GGGAATTCTTAGGTCTTGGGTGTGTAGA3′P2<SEQ ID NO.4>: 5′GGGAATTCTTAGGTCTTGGGTGTGTAGA3′
(2)含CTB与人胰岛素B链融合基因的重组家蚕杆状病毒BmBacCTBINB的获得:将转移质粒pBac-CTBINB与家蚕核型多角体病毒DNA进行共转染家蚕(Bombyx mori)细胞BmN,进行空斑和Southern点杂交筛选,筛选出含CTB与人胰岛素B链融合基因的重组杆状病毒BmBacCTBINB。该病毒已提交中国微生物菌种保藏管理委员会普通微生物中心保存,保藏日期为2004年4月22日,保藏编号为CGMCC No.1138。(2) Obtaining the recombinant silkworm baculovirus BmBacCTBINB containing the fusion gene of CTB and human insulin B chain: the transfer plasmid pBac-CTBINB and the silkworm nuclear polyhedrosis virus DNA were co-transfected into the silkworm (Bombyx mori) cell BmN, and empty The recombinant baculovirus BmBacCTBINB containing the fusion gene of CTB and human insulin B chain was screened by plaque and Southern dot hybridization. The virus has been submitted to the General Microorganism Center of the China Microbiological Culture Collection Management Committee for preservation. The preservation date is April 22, 2004, and the preservation number is CGMCC No.1138.
(3)CTB与人胰岛素B链融合蛋白在家蚕中的表达:将重组杆状病毒BmBacCTBINB感染BmN家蚕细胞进行病毒扩增,然后将扩增后的重组杆状病毒BmBacCTBINB注射至家蚕幼虫和蛹体内。(3) Expression of CTB and human insulin B-chain fusion protein in silkworm: Infect BmN silkworm cells with recombinant baculovirus BmBacCTBINB for virus amplification, and then inject the amplified recombinant baculovirus BmBacCTBINB into silkworm larvae and pupae .
(4)CTB与人胰岛素B链融合蛋白在草莓中的表达:将植物转移质粒pBI-CTBINB用电激方法导入根癌农杆菌,通过根癌农杆菌与茎尖共培养,在卡那霉素培养基筛选转基因植株。(4) Expression of CTB and human insulin B-chain fusion protein in strawberry: the plant transfer plasmid pBI-CTBINB was introduced into Agrobacterium tumefaciens by electric shock method, co-cultivated by Agrobacterium tumefaciens and shoot tips, and kanamycin Media for screening transgenic plants.
本发明的有益效果是:用家蚕和草莓高效表达CTB与人胰岛素B链融合蛋白,比直接从原核生物中表达的CTB与人胰岛素B链融合蛋白活性高,家蚕是可以无菌大规模饲养经济昆虫,可以低成本地大规模饲养,而且不会造成公害,蚕体中有多种天然蛋白质保护剂,对表达产物有保护作用,使基因表达产物十分稳定;草莓则大规模栽培,可以鲜食(而马铃薯和烟草等不能鲜食)。可以家蚕和草莓生产的融合蛋白可以作为口服或鲜食疫苗,为患者解除了注射的痛苦和被感染的威胁。The beneficial effect of the present invention is: the fusion protein of CTB and human insulin B chain is efficiently expressed by silkworm and strawberry, which is more active than the fusion protein of CTB and human insulin B chain expressed directly from prokaryotes, and silkworm can be sterile and large-scale breeding is economical Insects can be raised on a large scale at low cost without causing public nuisance. There are a variety of natural protein protectants in the silkworm body, which can protect the expression products and make the gene expression products very stable; strawberries are cultivated on a large scale and can be eaten fresh (And potatoes and tobacco cannot be eaten fresh). The fusion protein produced by silkworm and strawberry can be used as an oral or fresh vaccine, which relieves patients from the pain of injection and the threat of infection.
附图说明 Description of drawings
图1是含CTB与人胰岛素B链融合基因的昆虫杆状病毒转移质粒pBac-CTB-INB(图注说明:AcMNPV/AcNPV:苜蓿银纹夜蛾多角体病毒多角体启动子5′端/3′端旁侧序列;P:苜蓿银纹夜蛾多角体病毒多角体启动子;A(Polyhedin Poly A+signal)多角体蛋白基因聚腺苷酸化信号;M13 ori:M13噬菌体复制起始点;Amp:氨苄青霉素基因;ori:pUC复制起始点)Fig. 1 is the insect baculovirus transfer plasmid pBac-CTB-INB containing CTB and human insulin B chain fusion gene (illustration: AcMNPV/AcNPV: Autographa californica polyhedrosis virus polyhedrosis promoter 5' end/3 Side sequence at the ′ end; P: Autographa californica polyhedrosis virus polyhedron promoter; A (Polyhedin Poly A+signal) polyadenylation signal of polyhedrin gene; M13 ori: M13 phage replication origin; Amp: Ampicillin gene; ori: pUC origin of replication)
图2是家蚕表达产物的SDS-PAGE分析图谱,其中:M表示标准蛋白分子量标记;1表示BmCTBINB感染的家蚕血淋巴;2表示野生病毒感染的家蚕血淋巴。Fig. 2 is the SDS-PAGE analysis pattern of the silkworm expression product, wherein: M represents the standard protein molecular weight marker; 1 represents the hemolymph of the silkworm infected with BmCTBINB; 2 represents the hemolymph of the silkworm infected with the wild virus.
图3是家蚕表达产物的Western分析,其中:M表示标准蛋白分子量标记;1表示BmCTBINB感染的家蚕血淋巴;2表示野生病毒感染的家蚕血淋巴。Figure 3 is the Western analysis of the expression product of silkworm, wherein: M represents the standard protein molecular weight marker; 1 represents the hemolymph of silkworm infected with BmCTBINB; 2 represents the hemolymph of silkworm infected with wild virus.
具体实施方式 Detailed ways
下面通过实施例进一步阐述本发明,但并不限制本发明的保护范围。The present invention is further set forth below by embodiment, but protection scope of the present invention is not limited.
〔实施例1〕含有融合基因的转移质粒pBac-CTBINB和pBI-CTBINB的构建[Example 1] Construction of transfer plasmids pBac-CTBINB and pBI-CTBINB containing fusion genes
以pBac-CTBINS质粒(见200310121132.1专利申请说明书)为模板、P1和P2为引物进行扩增,反应条件为94℃预变性5分钟,扩增时94℃1分钟,57℃1分钟,72℃1分钟,反应30个循环,最后72℃保温10分钟,获得大小约为500bp左右的目的融合基因CTB-INB,且该基因5′和3′端分别带有BamHI和EcoRI位点。将上述目的融合基因进行BamHI和EcoRI双酶切后连在同样被BamHI和EcoRI酶切的pBacPAK8(CLONTECH公司)上,构建含CTB与人胰岛素B链基因的杆状病毒转移质粒pBac-CTBINB,经酶切分析和PCR鉴定基因正确插入后,经过自动序列测定表明构建的融合基因序列完全正确。将pBac-CTBINB经BamHI和SacI双酶切后,连接在同样被BamHI和SacI双酶切的转移载体pBI121(CLONTECH公司)上,构建含CTB与人胰岛素B链融合基因的植物转移质粒pBI-CTBINB。The pBac-CTBINS plasmid (see 200310121132.1 patent application specification) was used as a template and P1 and P2 were used as primers for amplification. The reaction conditions were pre-denaturation at 94°C for 5 minutes, amplification at 94°C for 1 minute, 57°C for 1 minute, and 72°C for 1 minute. Minutes, react for 30 cycles, and finally incubate at 72°C for 10 minutes to obtain the target fusion gene CTB-INB with a size of about 500 bp, and the 5' and 3' ends of the gene have BamHI and EcoRI sites respectively. The above-mentioned target fusion gene was digested with BamHI and EcoRI and connected to pBacPAK8 (CLONTECH Company) which was also digested with BamHI and EcoRI to construct the bacmid transfer plasmid pBac-CTBINB containing CTB and human insulin B chain gene. After enzyme digestion analysis and PCR identified the correct insertion of the gene, automatic sequence determination showed that the sequence of the constructed fusion gene was completely correct. After pBac-CTBINB was digested by BamHI and SacI, it was connected to the transfer vector pBI121 (CLONTECH Company) which was also digested by BamHI and SacI, and the plant transfer plasmid pBI-CTBINB containing the fusion gene of CTB and human insulin B chain was constructed. .
〔实施例2〕CTB与人胰岛素B链融合基因的重组杆状病毒的获得[Example 2] Obtaining of recombinant baculovirus of fusion gene of CTB and human insulin B chain
取5ul含CTB与人胰岛素B链融合基因的昆虫杆状病毒转移质粒pBac-CTBINB和6ul野生家蚕核型多角体病毒DNA进行共转染。取6ul Lipofectin(GIBCOBRL公司)加入100ul无血清的TC-100培养基混均。将事先培养在35mm Dish中的BmN细胞用无血清的TC-100(GIBCOBRL公司)培养基洗涤两次,并逐滴加入转移质粒和Lipofectin混合物,27℃培养4-5天,收取上清进行第一轮空斑筛选。取5ul上清感染35mm Dish中的BmN细胞,1小时后弃去上清加入等量混合的TC-100培养基和低熔点琼脂糖。4-5天后挑取空斑,感染Bm N细胞3-4天,保存上清,细胞用NaOH裂解用于Southern杂交,取阳性克隆的上清进行10轮空斑筛选。取阳性克隆的上清感染Bm N细胞扩增。即可得到大量的含CTB与人胰岛素B链融合基因的重组杆状病毒。Take 5ul insect baculovirus transfer plasmid pBac-CTBINB containing CTB and human insulin B-chain fusion gene and 6ul wild silkworm nuclear polyhedrosis virus DNA for co-transfection. Get 6ul Lipofectin (GIBCOBRL company) and add 100ul serum-free TC-100 medium and mix. The BmN cells previously cultured in a 35mm Dish were washed twice with serum-free TC-100 (GIBCOBRL company) medium, and the transfer plasmid and Lipofectin mixture was added dropwise, cultured at 27°C for 4-5 days, and the supernatant was collected for the second stage. One round of plaque screening. Take 5ul of the supernatant to infect the BmN cells in a 35mm Dish, discard the supernatant after 1 hour and add an equal amount of mixed TC-100 medium and low melting point agarose. Pick plaques after 4-5 days, infect BmN cells for 3-4 days, save the supernatant, lyse the cells with NaOH for Southern hybridization, and take the supernatant of positive clones for 10 rounds of plaque screening. The supernatant of positive clones was taken to infect BmN cells for expansion. A large number of recombinant baculoviruses containing fusion genes of CTB and human insulin B chain can be obtained.
〔实施例3〕CTB与人胰岛素B链融合基因在家蚕幼虫和蛹中的表达[Example 3] Expression of CTB and human insulin B chain fusion gene in silkworm larvae and pupae
取扩增的含CTB与人胰岛素B链融合基因的重组杆状病毒注射到五龄家蚕(Bombyx mori)幼虫和蛹中,每头注射2ul左右(滴度为1×107/ml),分别取24、48、72、96、120和144小时表达的家蚕淋巴和蛹血,5000rpm 5min离心后取上清,用PBS pH7.4稀释10倍后,加入等体积的2×蛋白质上样缓冲液(100Mm Tris.HCl,4% SDS,0.1%溴酚蓝,10%甘油),取20ul进行SDS-PAGE分析,见附图2。结果表明,CTB与人胰岛素B链融合蛋白在家蚕和蛹中获得高效表达,经Western杂交(附图3)表明表达产物分子量为18kD。将家蚕幼虫和蛹体含有表达的CTB与人胰岛素B链融合蛋白的血淋巴,高速冷冻离心,取上清。稀释1000倍后包被酶标板,同时以CTB为标准品,按照常规的ELISA步骤操作,其中兔抗CT一抗(购自SIGMA公司)稀释5000倍,山羊抗兔二抗(购自华美生物工程公司)稀释1000倍,用OPD(购自上海化学试剂公司)显色,于492nm处测定OD值,结果表明幼虫和蛹体表达的目的蛋白有很强的免疫活性,表达量分别达到380μg/ml和400μg/ml。Take the amplified recombinant baculovirus containing the fusion gene of CTB and human insulin B chain and inject it into the fifth instar silkworm (Bombyx mori) larvae and pupae, inject about 2 ul per head (titer is 1×10 7 /ml), respectively Take the silkworm lymph and pupal blood expressed at 24, 48, 72, 96, 120 and 144 hours, centrifuge at 5000rpm for 5min, take the supernatant, dilute 10 times with PBS pH7.4, add an equal volume of 2× protein loading buffer (100Mm Tris.HCl, 4% SDS, 0.1% bromophenol blue, 10% glycerol), take 20ul for SDS-PAGE analysis, see Figure 2. The results showed that the fusion protein of CTB and human insulin B chain was highly expressed in silkworm and pupae, and the molecular weight of the expressed product was 18kD by Western hybridization (accompanying drawing 3). The hemolymph of silkworm larvae and pupal bodies containing the fusion protein of CTB and human insulin B chain was subjected to high-speed freezing and centrifugation, and the supernatant was taken. Diluted 1000 times and then coated the microtiter plate. At the same time, CTB was used as a standard, and the routine ELISA procedure was followed, wherein the rabbit anti-CT primary antibody (purchased from SIGMA) was diluted 5000 times, and the goat anti-rabbit secondary antibody (purchased from Huamei Biotechnology Co., Ltd.) was diluted 5000 times. engineering company) was diluted 1000 times, developed color with OPD (purchased from Shanghai Chemical Reagent Company), and measured OD value at 492nm. ml and 400 μg/ml.
〔实施例4〕CTB与人胰岛素B链融合蛋白在草莓中的表达[Example 4] Expression of fusion protein of CTB and human insulin B chain in strawberry
将植物转移质粒pBI-CTBINB用电激方法导入根癌农杆菌LBA4404(CLONTECH公司),通过根癌农杆菌与草莓茎尖共培养将其导入草莓中,在筛选培养基上筛选,筛选培养基是含有0.6mg/L IAA,1.5mg/L BA,500mg/L羧苄霉素和100mg/L卡那霉素等的MS琼脂培养基,在28℃,16h/8h的光暗周期下培养2-4个月后,将转基因小苗转移到含有100mg/L卡那霉素的MS培养基上,使其生根,最后,将再生小苗移到温室获得了转基因植株,通过Southern杂交和PCR技术确认CTB与人胰岛素B链融合基因已整合在草莓基因组中,PCR技术鉴定的引物为P1和P2,按照《分子克隆》(Sambrook等,金冬雁等翻译,科学出版社,1992)的常规方法进行操作。通过对转基因植株果实提取蛋白质,加入等体积的2×蛋白质上样缓冲液(100Mm Tris.HCl,4% SDS,0.1%溴酚蓝,10%甘油),取20ul进行SDS-PAGE分析和Wersten印迹分析。从结果可以看出,CTB与人胰岛素B链融合基因在草莓果实中表达产物为18kD左右,与预测大小一致。对CTB与人胰岛素B链融合的表达产物进行免疫活性鉴定(操作方法同实施例3),结果表明表达产物具有很强的免疫活性,通过CTB标准品可以计算得出在草莓果实中的表达量达到占可溶性蛋白含量的0.5%。The plant transfer plasmid pBI-CTBINB was introduced into Agrobacterium tumefaciens LBA4404 (CLONTECH company) by electric shock method, and introduced into strawberries through co-cultivation of Agrobacterium tumefaciens and strawberry shoot tips, and screened on the screening medium. The screening medium was MS agar medium containing 0.6mg/L IAA, 1.5mg/L BA, 500mg/L carbenicillin and 100mg/L kanamycin, etc., cultured at 28°C under a light-dark cycle of 16h/8h for 2- After 4 months, the transgenic seedlings were transferred to MS medium containing 100mg/L kanamycin to make them take root. Finally, the regenerated seedlings were moved to the greenhouse to obtain transgenic plants. It was confirmed by Southern hybridization and PCR techniques that CTB and The human insulin B-chain fusion gene has been integrated in the strawberry genome, and the primers identified by PCR technology are P1 and P2, which are operated according to the conventional method of "Molecular Cloning" (Sambrook et al., translated by Jin Dongyan, etc., Science Press, 1992). Extract protein from transgenic plant fruit, add an equal volume of 2× protein loading buffer (100Mm Tris.HCl, 4% SDS, 0.1% bromophenol blue, 10% glycerol), take 20ul for SDS-PAGE analysis and Wersten blotting analyze. It can be seen from the results that the expression product of CTB and human insulin B chain fusion gene in strawberry fruit is about 18kD, which is consistent with the predicted size. Immune activity identification of the expression product fused with CTB and human insulin B chain (operation method is the same as in Example 3), the result shows that the expression product has strong immune activity, and the expression level in strawberry fruit can be calculated by CTB standard Up to 0.5% of the soluble protein content.
〔实施例5〕家蚕幼虫蚕蛹及草莓果实中表达的CTB与人胰岛素B链融合蛋白效果的动物试验〔Example 5〕The animal test of the CTB and human insulin B-chain fusion protein effect expressed in silkworm larva silkworm chrysalis and strawberry fruit
在家蚕幼虫和蛹体表达CTB与人胰岛素B链融合蛋白,经过过滤(100KD超滤),16000rmp和35000rmp离心后经冷冻干燥后,以家蚕幼虫和家蚕蛹为填充料配制成口服药物,草莓果实则研磨后直接用于口服动物试验。将4周龄雌NOD小鼠随机分成4组,每组5只,从第5周开始喂服,剂量为100μg/鼠,每周给药2次,连续喂5周。以口服给正常的蚕血淋巴和草莓果实为阴性对照,第10周处死小鼠,取小鼠胰岛作组织病理切片,观察胰岛炎发生情况,并作相应评分。结果表明给药组的小鼠胰岛炎指数为1.5±1.3,而对照组的小鼠胰岛炎指数高达为4.2±1.7,给药组胰岛炎显著低于对照小鼠。Express CTB and human insulin B-chain fusion protein in silkworm larvae and pupae, filter (100KD ultrafiltration), centrifuge at 16000rmp and 35000rmp, freeze-dry, and use silkworm larvae and silkworm pupae as fillers to prepare oral medicine, strawberry fruit Then it is directly used for oral animal experiments after grinding. The 4-week-old female NOD mice were randomly divided into 4 groups, 5 in each group, and were fed from the 5th week at a dose of 100 μg/mouse, administered twice a week for 5 consecutive weeks. Oral administration of normal silkworm hemolymph and strawberry fruit was used as a negative control, and the mice were sacrificed at the 10th week, and the islets of the mice were taken for histopathological sections to observe the occurrence of insulitis and score accordingly. The results showed that the insulitis index of the mice in the administration group was 1.5±1.3, while the insulitis index of the mice in the control group was as high as 4.2±1.7, and the insulitis index in the administration group was significantly lower than that in the control mice.
序列表sequence listing
<110>浙江大学<110> Zhejiang University
<120>一种融合基因、其表达的蛋白及其制备方法<120> A fusion gene, its expressed protein and its preparation method
<140>200410056850.X<140>200410056850.X
<141>2004-08-25<141>2004-08-25
<160>4<160>4
<210>1<210>1
<211>477<211>477
<212>DNA<212>DNA
<213>人工序列<213> Artificial sequence
<400>1<400>1
<210>2<210>2
<211>158<211>158
<212>PRT<212>PRT
<213>人工序列<213> Artificial sequence
<400>2<400>2
<210>3<210>3
<211>28<211>28
<212>DNA<212>DNA
<213>人工序列<213> Artificial sequence
<400>3<400>3
<210>4<210>4
<211>28<211>28
<212>DNA<212>DNA
<213>人工序列<213> Artificial sequence
<400>4<400>4
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200410056850XA CN100471955C (en) | 2004-08-25 | 2004-08-25 | A fusion gene, its expressed protein and its preparation method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200410056850XA CN100471955C (en) | 2004-08-25 | 2004-08-25 | A fusion gene, its expressed protein and its preparation method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1740325A CN1740325A (en) | 2006-03-01 |
CN100471955C true CN100471955C (en) | 2009-03-25 |
Family
ID=36092857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB200410056850XA Expired - Fee Related CN100471955C (en) | 2004-08-25 | 2004-08-25 | A fusion gene, its expressed protein and its preparation method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100471955C (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101353663B (en) * | 2008-03-12 | 2012-04-25 | 浙江大学 | Anti-I type diabetes fuse protein and preparation thereof |
CN103820477B (en) * | 2014-01-15 | 2017-01-25 | 浙江大学 | Fusion protein of CTB (Cellulose Tribenzoate), human insulin and glutamic acid decarboxylase 3p531 fragments and application thereof |
WO2016161983A1 (en) * | 2015-04-10 | 2016-10-13 | 中国医学科学院药物研究所 | Fusion carrier protein and application thereof in promoting target protein or polypeptide expression |
CN107474141A (en) * | 2017-04-14 | 2017-12-15 | 北京百华百汇生物科技有限公司 | Glicetin 1 acceptor excitomotor fusion protein and its application |
CN110256578B (en) * | 2019-06-24 | 2021-04-23 | 王跃驹 | Application of plant produced human cholera toxin B subunit (CTB) and proinsulin fusion protein quick-acting oral hypoglycemic capsule |
CN116726158A (en) * | 2023-04-24 | 2023-09-12 | 中国医学科学院医学生物学研究所 | Multi-epitope type 1diabetes vaccine and preparation method thereof |
-
2004
- 2004-08-25 CN CNB200410056850XA patent/CN100471955C/en not_active Expired - Fee Related
Non-Patent Citations (4)
Title |
---|
Genbank Accession Number:AF516347 gi:21668011. Rui,Y., et al.Genbank Accession Number:AF516347. 2002 * |
Production of a recombinant hybrid molecule of choleratoxin-B-subunit and proteolipid-protein-peptide for thetreatment of experimental encephalomyelitis. Yuki-Yoshikazu, et al.Biotechnology-and-Bioengineering,Vol.74 No.1. 2001 * |
幽门螺杆菌CAGA蛋白与CTB融合基因的克隆及其植物表达载体的构建. 姜云水等.科技通报,第20卷第3期. 2004 * |
霍乱毒素B亚基融合蛋白表达系统的构建. 曹诚等.生物化学杂志,第10卷第5期. 1994 * |
Also Published As
Publication number | Publication date |
---|---|
CN1740325A (en) | 2006-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7932056B2 (en) | Crustaceans as production systems for therapeutic proteins | |
AU2006271181B2 (en) | Mucosal or enteral administration of biologically active macromolecules | |
US8158855B2 (en) | Immunization of fish with plant-expressed recombinant proteins | |
CN100471955C (en) | A fusion gene, its expressed protein and its preparation method | |
WO2020060117A1 (en) | Composition for swine fever vaccine and preparation method therefor | |
CN104059927B (en) | Preparation method of newcastle disease glycoprotein viral antigen and products thereof | |
JP5008811B2 (en) | Immunoadhesives to prevent rhinovirus infection | |
JP7233662B2 (en) | Vaccine composition for preventing tuberculosis containing glycosylated AG85A protein and method for producing same | |
WO2018225917A1 (en) | Pyralid moth egg, producing method thereof, and method for producing recombinant protein by using pyralid moth egg | |
US6177075B1 (en) | Insect viruses and their uses in protecting plants | |
CA2232023A1 (en) | Expression cassettes and methods for delivery of animal vaccines | |
CN101353663A (en) | A kind of anti-type I diabetes fusion protein and its preparation method | |
CN101392027B (en) | Fusion protein for treating Alzheimer disease and preparation method thereof | |
WO2020213898A1 (en) | Porcine epidemic diarrhea (ped) virus vaccine composition and preparation method therefor | |
CN1629288A (en) | Recombinant silkworm baculovirus expressing CTB and human insulin fusion protein and its application | |
WO2022122036A1 (en) | Immunogen and pharmaceutical composition for sars-cov-2 virus, and use thereof | |
WO2020111814A1 (en) | Vaccine composition for preventing rabies, and preparation method therefor | |
CN103820477B (en) | Fusion protein of CTB (Cellulose Tribenzoate), human insulin and glutamic acid decarboxylase 3p531 fragments and application thereof | |
CN102876683A (en) | Conotoxin and biological preparation method and application thereof | |
WO2005096806A1 (en) | Rice plant having vaccine gene transferred thereinto | |
US20050268353A1 (en) | Insect viruses and their uses in protecting plants | |
WO2020256419A1 (en) | Recombinant vector for producing antibody for treating canine parvovirus infection, and use of same | |
WO2002043650A2 (en) | Systems and methods for delivering interferon to a subject | |
CN1427010A (en) | Preparation method of cholera toxin B sub unit | |
JP2008072948A (en) | Recombinant plant producing triinterferon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090325 Termination date: 20140825 |
|
EXPY | Termination of patent right or utility model |